Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Guizhou Bailing Group Pharmaceutical Co., Ltd. specializes in the production of traditional Chinese medicine and chemical pharmaceuticals, with a significant market presence in China. The company differentiates itself through its extensive R&D capabilities and a diverse product portfolio, including antibiotics and cardiovascular drugs, which are critical in addressing the healthcare needs of the growing Chinese population.
Guizhou Bailing generates revenue primarily through the sale of pharmaceuticals, leveraging its established distribution network across China. The company benefits from pricing power in its antibiotic segment, where demand remains robust despite competitive pressures. Its investment in R&D supports the development of new drugs, enhancing its competitive edge.
Regulatory approvals for new drugs
Changes in healthcare policy impacting drug pricing
Market share shifts in the antibiotic segment
R&D breakthroughs leading to new product launches
Regulatory changes affecting drug approval processes
Intense competition from both domestic and international pharmaceutical companies
Emergence of generic alternatives to key products
Pricing pressures from government healthcare reforms
Negative net margin indicating potential liquidity issues if losses continue
Low current ratio suggesting potential short-term liquidity challenges
moderate - as a pharmaceutical company, Guizhou Bailing's performance is somewhat insulated from economic downturns, but healthcare spending can be affected by broader economic conditions.
Interest rates impact the company's cost of capital, affecting R&D investments and potential acquisitions. Higher rates could lead to reduced demand for new drug development financing.
minimal - the company maintains a low debt-to-equity ratio, indicating limited reliance on external financing.
value - investors may be attracted to the stock due to its low valuation metrics despite recent performance struggles.
high - the stock has shown significant price fluctuations, particularly in response to earnings and regulatory news.